DUHS IRB Roster Update
Effective March 1, 2026 DUHS IRB will discontinue the public posting of detailed IRB rosters and replace them with a DUHS Compliance Assurance Statement similar to the approach used by peer institutions. Federal regulations from the U.S. Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP) as well as Good Clinical Practice (GCP) or other standards do not require public roster posting, only that rosters be maintained and made available to regulators or accrediting bodies upon request. Transitioning to a Compliance Assurance Statement and removing historical rosters from the website will improve accuracy, reduce administrative burden for both the DUHS IRB Office and study teams, and mitigate potential risk to IRB members associated with public identification. The new statement will provide sponsors with documentation affirming DUHS’s regulatory compliance and active IORG status while allowing internal rosters to remain the official source documentation.
IRB Office Relocation and Letterhead Update
The DUHS IRB office relocated in August 2025 from the 9th floor to the 10th floor of Erwin Square. All mail has been forwarded appropriately, so this transition should not disrupt correspondence or document delivery. All registrations and website information were updated in Fall 2025. Although the IRB letter templates retained the prior floor listing, this did not impact operations or correspondence, as the mail stop remained the same. The templates have now been updated as of February 17, 2026, to ensure consistency across all documentation. No action is required from study teams or sponsors, and this update should not impact ongoing studies or submissions.